Inventiva price target raised to $24 from $20 at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Inventiva (IVA) to $24 from $20 and keeps a Buy rating on the shares. If NATIV3 confirms Phase 2b results, lanifibranor could become “the oral backbone of MASH therapy,” says the analyst, who says that Inventiva’s analyst day reinforced lanifibranor’s differentiated positioning as the only oral, once daily pan PPAR agonist in late-stage development for MASH.